The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging.
 
Soumya Shekhar
Stock and Other Ownership Interests - Merck
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; Delcath Systems; Histosonics; Incyte; Ipsen; Rafael Pharmaceuticals; SERVIER; Taiho Oncology
Research Funding - Actuate Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Esanik (Inst); Exelixis (Inst); FibroGen (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); SERVIER (Inst); Syros Pharmaceuticals (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
Other Relationship - Rafael Pharmaceuticals (Inst)
 
Kathryn Howe
No Relationships to Disclose
 
Qingfeng Zhu
No Relationships to Disclose
 
Aya Kondo
Employment - Enable Medicine
Leadership - Enable Medicine
 
Helen L. Fedor
No Relationships to Disclose
 
Valerie Gunchick
No Relationships to Disclose
 
Naziheh Assarzadegan
No Relationships to Disclose
 
Nilofer Saba Azad
Stock and Other Ownership Interests - Haystack Oncology; Irazu; Tempus
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Taiho Pharmaceutical; Tempus
Speakers' Bureau - AstraZeneca
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Mark Yarchoan
Leadership - Adventris Pharmaceuticals
Stock and Other Ownership Interests - Adventris Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Marina Baretti
Consulting or Advisory Role - Exelixis; Incyte